{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,5]],"date-time":"2025-12-05T18:32:05Z","timestamp":1764959525428,"version":"3.46.0"},"reference-count":45,"publisher":"Public Library of Science (PLoS)","issue":"12","license":[{"start":{"date-parts":[[2025,12,5]],"date-time":"2025-12-05T00:00:00Z","timestamp":1764892800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS One"],"abstract":"<jats:sec id=\"sec001\">\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Controversy exists about the radiological follow-up of the spinal cord in MS, since cord lesions are mostly symptomatic, but there are also reports that 10% \u2212 25% are asymptomatic. Therefore, a need exists for biomarkers to identify patients prone to future cord involvement where routine cord imaging at follow-up is warranted. Elevated intrathecal IgM has been shown to be cross-sectionally associated with more cord lesions. This study investigated whether there also is a longitudinal relation.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"sec002\">\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Relapse-onset MS patients with baseline CSF and spinal MRI available were retrospectively identified. Cross-sectional associations between intrathecal immunoglobulin production and cord lesions were assessed. For the subgroup where follow-up spinal MRIs were available, Andersen\u2013Gill time-to-event models were used to estimate the risk of new cord lesions based on CSF makers and important covariates.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"sec003\">\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>394 patients had baseline CSF and cord imaging available, of which 253 had CSF and serum IgG data available, 139 IgM data and 138 both IgG and IgM data. At baseline, patients with intrathecal IgG (IgG IF+; 175 out of 253) and IgM production (IgM IF+; 44 out of 139) had more cord lesions (IgG IF+, mean 1.30 vs. 0.85 spinal cord lesions, p\u2009&lt;\u20090.01; IgM IF+ mean 1.64 vs. 0.91 spinal cord lesions, p\u2009&lt;\u20090.05). After correction for important covariates, only IgM IF+ (IgM IF+ \u03b2\u2009=\u20090.53, p\u2009=\u20090.02; IgG IF+ \u03b2\u2009=\u20090.38, p\u2009=\u20090.13) was a statistically significant positive predictor for more spinal cord lesions at baseline. For 66 patients follow-up cord imaging was available with a median follow-up time of 2 years (IQR 1.1\u20134.2). Longitudinally, there was no statistically significant association of IgM and IgG IF+ with new future cord lesions.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"sec004\">\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>While intrathecal IgM production is cross-sectionally independently associated with spinal cord lesions, this study does not support a role for predicting new cord lesions at follow-up.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1371\/journal.pone.0337515","type":"journal-article","created":{"date-parts":[[2025,12,5]],"date-time":"2025-12-05T18:27:11Z","timestamp":1764959231000},"page":"e0337515","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":0,"title":["Spinal cord lesions in relapsing-remitting multiple sclerosis: Prognostic value of intrathecal production of immunoglobulins"],"prefix":"10.1371","volume":"20","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0954-1834","authenticated-orcid":true,"given":"Daniel","family":"Kreiter","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Niels","family":"Franken","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-6141-5261","authenticated-orcid":true,"given":"Demmie","family":"Bouweriks","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stephanie","family":"Knippenberg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Raymond","family":"Hupperts","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Oliver","family":"Gerlach","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"340","published-online":{"date-parts":[[2025,12,5]]},"reference":[{"issue":"8","key":"pone.0337515.ref001","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1016\/S1474-4422(21)00095-8","article-title":"2021 MAGNIMS-CMSC-NAIMS consensus recommendations on the use of MRI in patients with multiple sclerosis","volume":"20","author":"MP Wattjes","year":"2021","journal-title":"Lancet Neurol"},{"issue":"12","key":"pone.0337515.ref002","doi-asserted-by":"crossref","first-page":"3031","DOI":"10.1007\/s00415-019-09526-3","article-title":"Spinal cord lesions are frequently asymptomatic in relapsing-remitting multiple sclerosis: a retrospective MRI survey","volume":"266","author":"F Granella","year":"2019","journal-title":"J Neurol"},{"issue":"6","key":"pone.0337515.ref003","doi-asserted-by":"crossref","first-page":"782","DOI":"10.1177\/1352458515599246","article-title":"Relevance of asymptomatic spinal MRI lesions in patients with multiple sclerosis","volume":"22","author":"C Zecca","year":"2016","journal-title":"Mult Scler"},{"issue":"2","key":"pone.0337515.ref004","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1001\/jamaneurol.2014.3537","article-title":"Evaluation of no evidence of disease activity in a 7-year longitudinal multiple sclerosis cohort","volume":"72","author":"DL Rotstein","year":"2015","journal-title":"JAMA Neurol"},{"issue":"2","key":"pone.0337515.ref005","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/S1474-4422(17)30470-2","article-title":"Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria","volume":"17","author":"AJ Thompson","year":"2018","journal-title":"Lancet Neurol"},{"issue":"6","key":"pone.0337515.ref006","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1001\/archneur.62.6.865","article-title":"Recommended standard of cerebrospinal fluid analysis in the diagnosis of multiple sclerosis: a consensus statement","volume":"62","author":"MS Freedman","year":"2005","journal-title":"Arch Neurol"},{"issue":"1","key":"pone.0337515.ref007","doi-asserted-by":"crossref","DOI":"10.1212\/NXI.0000000000200052","article-title":"Serum GFAP and NfL Levels Differentiate Subsequent Progression and Disease Activity in Patients With Progressive Multiple Sclerosis","volume":"10","author":"C Barro","year":"2022","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"issue":"10","key":"pone.0337515.ref008","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1016\/S1474-4422(25)00270-4","article-title":"Diagnosis of multiple sclerosis: 2024 revisions of the McDonald criteria","volume":"24","author":"X Montalban","year":"2025","journal-title":"Lancet Neurol"},{"issue":"6","key":"pone.0337515.ref009","doi-asserted-by":"crossref","first-page":"814","DOI":"10.1002\/ana.26348","article-title":"Intrathecal IgM Synthesis Is Associated with Spinal Cord Manifestation and Neuronal Injury in Early MS","volume":"91","author":"J Oechtering","year":"2022","journal-title":"Ann Neurol"},{"key":"pone.0337515.ref010","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.clineuro.2017.05.026","article-title":"Intrathecal IgM index correlates with a severe disease course in multiple sclerosis: Clinical and MRI results","volume":"160","author":"S Ozakbas","year":"2017","journal-title":"Clin Neurol Neurosurg"},{"issue":"1","key":"pone.0337515.ref011","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1017\/S0317167100035757","article-title":"Effect of methylprednisolone on CSF IgG parameters, myelin basic protein and anti-myelin basic protein in multiple sclerosis exacerbations","volume":"13","author":"KG Warren","year":"1986","journal-title":"Can J Neurol Sci"},{"issue":"3","key":"pone.0337515.ref012","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1111\/j.1600-0404.1992.tb05088.x","article-title":"CSF myelin basic protein, IgG and IgM levels in 101 MS patients before and after treatment with high-dose intravenous methylprednisolone","volume":"86","author":"ST Frequin","year":"1992","journal-title":"Acta Neurol Scand"},{"key":"pone.0337515.ref013","doi-asserted-by":"crossref","first-page":"104994","DOI":"10.1016\/j.msard.2023.104994","article-title":"Effect of disease-modifying treatment on spinal cord lesion formation in multiple sclerosis: A retrospective observational study","volume":"79","author":"D Kreiter","year":"2023","journal-title":"Mult Scler Relat Disord"},{"issue":"3","key":"pone.0337515.ref014","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1177\/1352458517751647","article-title":"Impact of 3 Tesla MRI on interobserver agreement in clinically isolated syndrome: A MAGNIMS multicentre study","volume":"25","author":"MH Hagens","year":"2019","journal-title":"Mult Scler"},{"key":"pone.0337515.ref015","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.jns.2008.11.009","article-title":"Spinal cord lesions and clinical status in multiple sclerosis: A 1.5 T and 3 T MRI study","volume":"279","author":"JM Stankiewicz","year":"2009","journal-title":"J Neurol Sci"},{"issue":"3","key":"pone.0337515.ref016","article-title":"Three-Tesla MRI does not improve the diagnosis of multiple sclerosis: A multicenter study","volume":"91","author":"MHJ Hagens","year":"2018","journal-title":"Neurology"},{"issue":"3","key":"pone.0337515.ref017","first-page":"99","article-title":"Cerebrospinal fluid--physiology, analysis and interpretation of protein patterns for diagnosis of neurological diseases","volume":"4","author":"H Reiber","year":"1998","journal-title":"Mult Scler"},{"issue":"3","key":"pone.0337515.ref018","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1177\/135245859800400304","article-title":"The intrathecal, polyspecific and oligoclonal immune response in multiple sclerosis","volume":"4","author":"H Reiber","year":"1998","journal-title":"Mult Scler"},{"issue":"7","key":"pone.0337515.ref019","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1001\/jamaneurol.2019.0905","article-title":"Association of Intrathecal Immunoglobulin G Synthesis With Disability Worsening in Multiple Sclerosis","volume":"76","author":"C Gasperi","year":"2019","journal-title":"JAMA Neurol"},{"issue":"3","key":"pone.0337515.ref020","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1002\/ana.26137","article-title":"Intrathecal Immunoglobulin M Synthesis is an Independent Biomarker for Higher Disease Activity and Severity in Multiple Sclerosis","volume":"90","author":"J Oechtering","year":"2021","journal-title":"Ann Neurol"},{"issue":"11","key":"pone.0337515.ref021","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1136\/jnnp-2023-333307","article-title":"Routine CSF parameters as predictors of disease course in multiple sclerosis: an MSBase cohort study","volume":"95","author":"C Dekeyser","year":"2024","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"1","key":"pone.0337515.ref022","doi-asserted-by":"crossref","first-page":"14987","DOI":"10.1038\/s41598-021-94423-x","article-title":"Cerebrospinal fluid oligoclonal immunoglobulin gamma bands and long-term disability progression in multiple sclerosis: a retrospective cohort study","volume":"11","author":"VD Karrenbauer","year":"2021","journal-title":"Sci Rep"},{"issue":"5","key":"pone.0337515.ref023","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1177\/1352458512459684","article-title":"Oligoclonal bands and cerebrospinal fluid markers in multiple sclerosis: associations with disease course and progression","volume":"19","author":"P Lourenco","year":"2013","journal-title":"Mult Scler"},{"issue":"4","key":"pone.0337515.ref024","doi-asserted-by":"crossref","DOI":"10.1212\/NXI.0000000000000573","article-title":"CSF parameters associated with early MRI activity in patients with MS","volume":"6","author":"A Klein","year":"2019","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"pone.0337515.ref025","doi-asserted-by":"crossref","first-page":"569827","DOI":"10.3389\/fncel.2020.569827","article-title":"Cerebrospinal Fluid IgM Levels in Association With Inflammatory Pathways in Multiple Sclerosis Patients","volume":"14","author":"R Magliozzi","year":"2020","journal-title":"Front Cell Neurosci"},{"issue":"2","key":"pone.0337515.ref026","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1002\/ana.10441","article-title":"Intrathecal IgM synthesis is a prognostic factor in multiple sclerosis","volume":"53","author":"LM Villar","year":"2003","journal-title":"Ann Neurol"},{"issue":"1","key":"pone.0337515.ref027","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1172\/JCI22833","article-title":"Intrathecal synthesis of oligoclonal IgM against myelin lipids predicts an aggressive disease course in MS","volume":"115","author":"LM Villar","year":"2005","journal-title":"J Clin Invest"},{"issue":"8","key":"pone.0337515.ref028","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1136\/jnnp.2005.086116","article-title":"Intrathecal IgM production at clinical onset correlates with a more severe disease course in multiple sclerosis","volume":"77","author":"P Perini","year":"2006","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"pone.0337515.ref029","doi-asserted-by":"crossref","first-page":"104573","DOI":"10.1016\/j.ebiom.2023.104573","article-title":"Kappa free light chain and neurofilament light independently predict early multiple sclerosis disease activity-a cohort study","volume":"91","author":"H Hegen","year":"2023","journal-title":"EBioMedicine"},{"key":"pone.0337515.ref030","doi-asserted-by":"crossref","first-page":"105747","DOI":"10.1016\/j.msard.2024.105747","article-title":"Serum NfL and GFAP are weak predictors of long-term multiple sclerosis prognosis: A 6-year follow-up","volume":"89","author":"X Ayrignac","year":"2024","journal-title":"Mult Scler Relat Disord"},{"issue":"1","key":"pone.0337515.ref031","doi-asserted-by":"crossref","first-page":"10381","DOI":"10.1038\/s41598-020-67504-6","article-title":"Serum neurofilament light chain predicts long term clinical outcomes in multiple sclerosis","volume":"10","author":"S Thebault","year":"2020","journal-title":"Sci Rep"},{"issue":"3","key":"pone.0337515.ref032","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1016\/S1474-4422(22)00009-6","article-title":"Serum neurofilament light chain for individual prognostication of disease activity in people with multiple sclerosis: a retrospective modelling and validation study","volume":"21","author":"P Benkert","year":"2022","journal-title":"Lancet Neurol"},{"issue":"11","key":"pone.0337515.ref033","doi-asserted-by":"crossref","first-page":"1359","DOI":"10.1001\/jamaneurol.2019.2137","article-title":"Association Between Serum Neurofilament Light Chain Levels and Long-term Disease Course Among Patients With Multiple Sclerosis Followed up for 12 Years","volume":"76","author":"E Cant\u00f3","year":"2019","journal-title":"JAMA Neurol"},{"issue":"12","key":"pone.0337515.ref034","doi-asserted-by":"crossref","first-page":"4084","DOI":"10.1093\/brain\/awae260","article-title":"Serum biomarkers at disease onset for personalized therapy in multiple sclerosis","volume":"147","author":"E Monreal","year":"2024","journal-title":"Brain"},{"issue":"4","key":"pone.0337515.ref035","doi-asserted-by":"crossref","DOI":"10.1212\/NXI.0000000000001005","article-title":"Kappa-Free Light Chains in CSF Predict Early Multiple Sclerosis Disease Activity","volume":"8","author":"K Berek","year":"2021","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"pone.0337515.ref036","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.msard.2019.02.001","article-title":"Kappa free light chains could predict early disease course in multiple sclerosis","volume":"30","author":"D Vecchio","year":"2019","journal-title":"Mult Scler Relat Disord"},{"issue":"11","key":"pone.0337515.ref037","doi-asserted-by":"crossref","first-page":"1496","DOI":"10.1177\/1352458516681503","article-title":"Prognostic value of free light chains lambda and kappa in early multiple sclerosis","volume":"23","author":"MM Voortman","year":"2017","journal-title":"Mult Scler"},{"key":"pone.0337515.ref038","doi-asserted-by":"crossref","first-page":"1223514","DOI":"10.3389\/fimmu.2023.1223514","article-title":"Kappa free light chains index in multiple sclerosis very long-term prognosis","volume":"14","author":"P Arroyo-Pereiro","year":"2023","journal-title":"Front Immunol"},{"issue":"4","key":"pone.0337515.ref039","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1212\/WNL.59.4.555","article-title":"Intrathecal IgM synthesis predicts the onset of new relapses and a worse disease course in MS","volume":"59","author":"LM Villar","year":"2002","journal-title":"Neurology"},{"key":"pone.0337515.ref040","doi-asserted-by":"crossref","first-page":"102382","DOI":"10.1016\/j.msard.2020.102382","article-title":"Impact of intrathecal IgG synthesis on neurological disability in patients with multiple sclerosis","volume":"45","author":"T Akaishi","year":"2020","journal-title":"Mult Scler Relat Disord"},{"issue":"1","key":"pone.0337515.ref041","doi-asserted-by":"crossref","first-page":"25540","DOI":"10.1038\/s41598-024-76969-8","article-title":"Intrathecal IgG and IgM synthesis correlates with neurodegeneration markers and corresponds to meningeal B cell presence in MS","volume":"14","author":"C Rodriguez-Mogeda","year":"2024","journal-title":"Sci Rep"},{"issue":"4","key":"pone.0337515.ref042","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1111\/bpa.12841","article-title":"B cell rich meningeal inflammation associates with increased spinal cord pathology in multiple sclerosis","volume":"30","author":"C Reali","year":"2020","journal-title":"Brain Pathol"},{"issue":"28","key":"pone.0337515.ref043","doi-asserted-by":"crossref","first-page":"7864","DOI":"10.1073\/pnas.1522730113","article-title":"Distinct oligoclonal band antibodies in multiple sclerosis recognize ubiquitous self-proteins","volume":"113","author":"SM Br\u00e4ndle","year":"2016","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"28","key":"pone.0337515.ref044","doi-asserted-by":"crossref","first-page":"7696","DOI":"10.1073\/pnas.1609246113","article-title":"Antibodies in multiple sclerosis oligoclonal bands target debris","volume":"113","author":"RC Winger","year":"2016","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"1","key":"pone.0337515.ref045","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1002\/ana.21524","article-title":"Immunoglobulins and complement in postmortem multiple sclerosis tissue","volume":"65","author":"MH Barnett","year":"2009","journal-title":"Ann Neurol"}],"container-title":["PLOS One"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0337515","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,5]],"date-time":"2025-12-05T18:27:18Z","timestamp":1764959238000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0337515"}},"subtitle":[],"editor":[{"given":"Karlo","family":"Toljan","sequence":"first","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2025,12,5]]},"references-count":45,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2025,12,5]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0337515","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,5]]}}}